ProMIS Neurosciences to Present at Conference, Details Mid-2026 Interim Analysis for PRECISE-AD
ProMIS Neurosciences CEO Neil Warma will present at the April 21 Bloom Burton & Co. healthcare investor conference. The company is on track to complete a six-month interim safety and biomarker analysis of its PRECISE-AD Phase 1b trial mid-2026, finish dosing by year-end and report top-line data in early 2027.
1. Conference Participation
ProMIS Neurosciences CEO Neil Warma will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21 in Toronto and engage in one-on-one meetings with investors. A webcast of the presentation will be available to registered attendees via the conference portal.
2. PRECISE-AD Trial Timeline
The company is set to complete a six-month interim safety and biomarker analysis of its PRECISE-AD Phase 1b trial in mid-2026, finish full patient dosing by year-end 2026 and deliver unblinded top-line results in early 2027.
3. PMN310 Lead Candidate
PMN310 is a humanized monoclonal antibody designed to selectively target toxic oligomers in Alzheimer’s disease, aiming to reduce amyloid-related imaging abnormalities and potentially improve efficacy over existing therapies. It received FDA Fast Track designation in July 2025.